Showing 41 - 50 of 154
Objective: The objective of this paper is to examine how well the QALY captures the health gains generated by cancer treatments, with particular focus on the methods for constructing QALYs preferred by NICE. Methods: Data were obtained using a keyword search of the MEDLINE database and a hand...
Persistent link: https://www.econbiz.de/10013018938
Antimicrobial resistance (AMR) is becoming a major global public health threat and has begun to command attention from European and US policy makers. An initial focus on monitoring AMR and conserving existing treatments by cutting down on misuse has been complemented by moves towards addressing...
Persistent link: https://www.econbiz.de/10013018940
Current pricing and reimbursement systems for diagnostics are not efficient. Prices for diagnostics often are driven by administrative practice and expected production cost. The purpose of this paper is to discuss how a value based pricing (VBP) framework that is being used to ensure efficient...
Persistent link: https://www.econbiz.de/10013019009
Objectives: This research was intended to explore whether wealth effects of drug interventions, including productivity gains and savings in other sectors, are considered in resource allocations by health technology assessment (HTA) agencies and government departments. It also analyses reasons...
Persistent link: https://www.econbiz.de/10013019280
In June 2006, a conference entitled Better Analysis for Better Decisions: Bridging the Gap Between Economic Evaluation and Healthcare Decision Making was held at McMaster University in honour of the late Bernie O'Brien. The papers presented by leading health economists were reviews of the use of...
Persistent link: https://www.econbiz.de/10013017905
Persistent link: https://www.econbiz.de/10009298444
Persistent link: https://www.econbiz.de/10012881698
Persistent link: https://www.econbiz.de/10012881704
This paper reviews the economic case for patents and the potential for differential pricing to increase affordability of on-patent drugs in developing countries while preserving incentives for innovation. Differential pricing, based on Ramsey pricing principles, is the second best efficient way...
Persistent link: https://www.econbiz.de/10014029957
Rational: The most significant initiative to address the innovation gap for neglected diseases affecting poor populations in poor countries has been the establishment of Public-Private Partnerships for product development (PD PPPs) which have been supported in conception and funding by a number...
Persistent link: https://www.econbiz.de/10014049885